Karen Horn - Eli Lilly Independent Director

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:3em;padding-top: 40px;;'>ELI</div>
LLY -- USA Stock  

Earning Report: 23rd of April 2020  

Dr. Karen N. Horn, Ph.D., is Independent Director of Eli Lilly Co. Ms. Horn is a former CEO with extensive experience in various segments of the financial industry, including banking and financial services. Through her forprofit and her publicprivate partnership work, she has significant experience in international economics and finance. Ms. Horn has extensive corporate governance experience through service on other public company boards in a variety of industries.
Age: 71  Director Since 2012      
317 276-2000  www.lilly.com

Karen Horn Latest Insider Activity

Management Efficiency

The company has Return on Asset of 0.23 % which means that on every $100 spent on asset it made $0.23 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.03 % implying that it generated $0.03 on every 100 dollars invested.
The company has 15.92 B in debt with debt to equity (D/E) ratio of 459.7 . This implies that the company may be unable to create cash to meet all of its financial commitments. Eli Lilly And has Current Ratio of 1.15 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Togo WestBristol Myers Squibb Company
Andreas PlantaNovartis AG
Paul RothmanMerck Company
Peter WendellMerck Company
Laurie GlimcherBristol Myers Squibb Company
Manvinder BangaGlaxoSmithKline PLC
Rochelle LazarusMerck Company
Judy LewentGlaxoSmithKline PLC
Michael GallagherAllergan Plc
Nesli BasgozAllergan Plc
Baroness VaderaAstrazeneca PLC
Tim JacksonSmithAstrazeneca PLC
Carla HillsGilead Sciences
Jacqueline BartonGilead Sciences
Craig ThompsonMerck Company
Scott DavisJohnson Johnson
Dennis AusielloPfizer
Tony MokAstrazeneca PLC
Karen VousdenBristol Myers Squibb Company
Frances FergussonPfizer
Pamela CraigMerck Company

Company Summary

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company was founded in 1876 and is headquartered in Indianapolis, Indiana. Eli Lilly operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 33625 people.Eli Lilly And Company (LLY) is traded on BATS Exchange in USA. It is located in Lilly Corporate Center, Indianapolis, IN 46285, United States and employs 33,625 people. Eli Lilly And Company was previously known as ELI LILLY Co and was traded on BATS Exchange under the symbol LLY. Eli Lilly is listed under Pharmaceutical Products category by Fama And French industry classification.

Eli Lilly And Leadership Team

Ellen Marram, Lead Independent DirectorView
Kathi Seifert, Independent DirectorView
Ralph Alvarez, Independent DirectorView
Jamere Jackson, Independent DirectorView
Joshua Smiley, Chief Financial Officer, Senior Vice PresidentView
Anat Hakim, Senior Vice President General CounselView
Fionnuala Walsh, Senior Vice President - Global QualityView
Johna Norton, Senior Vice President - Global QualityView
Juan Luciano, Lead Independent DirectorView
J Fyrwald, Independent DirectorView
Alfonso Zulueta, Senior Vice President and President - Emerging Markets businessView
Jeffrey Simmons, Senior Vice President and President - Elanco Animal HealthView
John Lechleiter, Chairman, CEO and PresView
Anne White, Senior Vice President and Presidentident - Lilly OncologyView
Karen Horn, Independent DirectorView
Leigh Pusey, Senior Vice President - Corporate Affairs and CommunicationsView
Melissa Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance OfficerView
Darren Carroll, Senior Vice President - Corporate Business DevelopmentView
Patrik Jonsson, Senior Vice President and President - Lilly Bio-MedicinesView
William Kaelin, Independent DirectorView
Karen Walker, Independent DirectorView
Christi Shaw, Senior Vice President and President - Lilly Bio-MedicinesView
Barton Peterson, Senior Vice President - Corporate Affairs and CommunicationsView
Derica Rice, CFO, Executive VP of Global Services, Member of Operations Committee and Member of Policy and Strategy CommitteeView
Enrique Conterno, Senior Vice President and President - Lilly Diabetes and President - Lilly USAView
Raul Alvarez, Independent DirectorView
Marschall Runge, Independent DirectorView
Michael Harrington, Executive Vice President, General CounselView
David Hoover, Independent DirectorView
Maria Crowe, President - Manufacturing OperationsView
Myles ONeill, Senior Vice President and President - Manufacturing OperationsView
David Ricks, Senior Vice President and Presidentident - Lilly Bio-MedicinesView
Daniel Skovronsky, Senior Vice President - Science and Technology, and President Lilly Research LaboratoriesView
Jan Lundberg, Executive VP of Science and Technology and President of Lilly Research LaboratoriesView
Carolyn Bertozzi, Independent DirectorView
Erik Fyrwald, Independent DirectorView
Aarti Shah, Senior Vice President - Chief Information and Digital OfficerView
Susan Mahony, Senior Vice President and President - Lilly OncologyView
Jackson Tai, Independent DirectorView
Michael Eskew, Independent DirectorView
Katherine Baicker, Independent DirectorView
Stephen Fry, Senior Vice President - Human Resources and DiversityView
Michael Mason, Senior Vice President and President Lilly DiabetesView
Franklyn Prendergast, Independent DirectorView

Stock Performance Indicators

Did you try this?

Run Competition Analyzer Now


Competition Analyzer

Analyze and compare many basic indicators for a group of related or unrelated entities
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Please also try Premium Stories module to follow macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page